Trial · NCT04968912
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
NCT04968912, Phase 2, Completed, Janssen Research & Development, LLC
3 sourcestrials-2026-11-12-0.4.0
Download JSON
Cite this record
ConductScience Library. A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS). Trials, record NCT04968912. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04968912
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
- NCT number
- NCT04968912
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 163 participants, actual
- Lead sponsor
- Janssen Research & Development, LLC
- Conditions
- Sjogren's Syndrome
- Interventions
- Placebo, Nipocalimab, Standard of Care Treatment
- First posted
- 2021-07-20
- Last updated
- 2026-11-05
- Other registries' IDs
- eudract:2021-000665-32
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24 | Baseline (Week 0), Week 24 | In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement. |
| Secondary | Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24 | Baseline (Week 0), Week 24 | Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms. |
| Secondary | Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24 | Baseline (Week 0), Week 24 | ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement. |
| Secondary | Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24 | Baseline (Week 0), Week 24 | In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement. |
| Secondary | Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24 | Baseline (Week 0), Week 24 | Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of \>= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms. |
| Secondary | Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24 | At Week 24 | Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of \>=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of \>=3 in clinESSDAI score (3), (ii) decrease of \>=1 point or \>=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of \>=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of \>=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of \>=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of \>=25% in rheumatoid factor/decrease of \>=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome). |
| Secondary | Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24 | At Week 24 | DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score \* domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of \>= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy). |
| Secondary | Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24 | At Week 24 | Percentage of participants with improvement from baseline in \>= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in \>= 3 of the following 5 categories: (i) clinESSDAI score less than (\<) 5 (low disease activity), (ii) decrease of \>= 1 point or \>= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (\<= 5 mm) and an increase of \>= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of \>= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of \>= 25% in rheumatoid factor or decrease of \>= 10% in IgG. |
| Secondary | Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit | Post first administration of study intervention (Week 0) up to Week 30 | An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment. |
| Secondary | Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit | Post first administration of study intervention (Week 0) up to Week 30 | Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin \< 20 grams per liter (g/L) (\< 2.0 grams per deciliter \[g/dL\]); applicable to participants who had albumin greater than (\>) 20 g/L at previous assessments. Those who entered with \< 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin \> 20 g/L or those who entered with albumin \< 20g/L and then had an increase in albumin \> 20 g/L which subsequently decreased to \< 20 g/L were reported as an AESI. |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04968912
GET https://conductscience.org/api/trials/v1/NCT04968912/registered?page=2